Boai NKY Pharmaceuticals Ltd - Asset Resilience Ratio
Boai NKY Pharmaceuticals Ltd (300109) has an Asset Resilience Ratio of 0.51% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Boai NKY Pharmaceuticals Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Boai NKY Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Boai NKY Pharmaceuticals Ltd (300109) total assets.
Liquid Assets Composition Over Time
This chart breaks down Boai NKY Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Boai NKY Pharmaceuticals Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥22.21 Million | 0.51% |
| Total Liquid Assets | CN¥22.21 Million | 0.51% |
Asset Resilience Insights
- Limited Liquidity: Boai NKY Pharmaceuticals Ltd maintains only 0.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Boai NKY Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Boai NKY Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP |
Specialty Chemicals | 1.69% |
|
Cngr Advanced Material Co Ltd
SHE:300919 |
Specialty Chemicals | 0.52% |
|
Supreme Petrochem Limited
NSE:SPLPETRO |
Specialty Chemicals | 8.22% |
|
5N Plus Inc.
TO:VNP |
Specialty Chemicals | 12.56% |
|
Cofco Biochemical Anhui Co Ltd
SHE:000930 |
Specialty Chemicals | 0.01% |
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488 |
Specialty Chemicals | 1.39% |
|
Jiangxi Guotai Civilian
SHG:603977 |
Specialty Chemicals | 12.39% |
|
Suzhou Shihua New Material Technology Co Ltd
SHG:688093 |
Specialty Chemicals | 25.17% |
Annual Asset Resilience Ratio for Boai NKY Pharmaceuticals Ltd (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Boai NKY Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.54% | CN¥23.79 Million ≈ $3.48 Million |
CN¥4.37 Billion ≈ $639.22 Million |
-0.16pp |
| 2024-12-31 | 0.71% | CN¥30.98 Million ≈ $4.53 Million |
CN¥4.37 Billion ≈ $639.77 Million |
-0.14pp |
| 2023-12-31 | 0.85% | CN¥34.20 Million ≈ $5.00 Million |
CN¥4.02 Billion ≈ $588.21 Million |
-0.01pp |
| 2022-12-31 | 0.86% | CN¥31.99 Million ≈ $4.68 Million |
CN¥3.71 Billion ≈ $543.41 Million |
-4.19pp |
| 2021-12-31 | 5.06% | CN¥201.71 Million ≈ $29.52 Million |
CN¥3.99 Billion ≈ $583.85 Million |
+3.97pp |
| 2020-12-31 | 1.09% | CN¥45.03 Million ≈ $6.59 Million |
CN¥4.15 Billion ≈ $606.61 Million |
+2.72pp |
| 2019-12-31 | -1.63% | CN¥-68.37 Million ≈ $-10.00 Million |
CN¥4.20 Billion ≈ $614.11 Million |
-1.22pp |
| 2018-12-31 | -0.41% | CN¥-9.48 Million ≈ $-1.39 Million |
CN¥2.30 Billion ≈ $337.02 Million |
-0.32pp |
| 2017-12-31 | -0.09% | CN¥-1.83 Million ≈ $-268.20K |
CN¥1.96 Billion ≈ $286.61 Million |
-3.22pp |
| 2016-12-31 | 3.13% | CN¥41.00 Million ≈ $6.00 Million |
CN¥1.31 Billion ≈ $191.68 Million |
+3.19pp |
| 2015-12-31 | -0.06% | CN¥-725.33K ≈ $-106.14K |
CN¥1.24 Billion ≈ $180.86 Million |
-- |
| 2010-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥357.81 Million ≈ $52.36 Million |
-- |
About Boai NKY Pharmaceuticals Ltd
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP) series products, vinyl methyl ether/maleic anhydride copolymer (PVM/MA, Euroster) copolymer, and oral care products; and medical technology services, such as early tumor screening, molecular diagnostics, and precisio… Read more